Article

Conventional LASIK affects night-driving performance

Washington, DC &#8212 Conventional LASIK for moderate myopia generally reduces night-driving performance, but the frequency of that effect differs between laser platforms, said Steve C. Schallhorn, MD.

April 18 - Washington, DC - Conventional LASIK for moderate myopia generally reduces night-driving performance, but the frequency of that effect differs between laser platforms, said Steve C. Schallhorn, MD.

He reported results from a study in which 75 patients were randomized to conventional myopic LASIK with one of four lasers: a VISX system, the Technolas 217 (B&L), the EC-5000 (Nidek), or the LADARVision 4000 (Alcon Laboratories).

Only patients with between -5 and -6 D of myopia were included. All underwent testing with a night driving simulator preoperatively and at 6 months after surgery. A series of 144 threshold measurements were made in each patient with each eye tested separately to detect and identify three different road hazards with and without a glare source.

For change in detection, patients who were treated with the Alcon or VISX lasers had less performance loss from pre- to postoperatively relative to the B&L and Nidek groups. Loss in ability to identify road hazards was least in the VISX group compared with the other three laser groups, which were all associated with similar changes in performance.

"Based on metrics provided by the National Highway Traffic Safety Administration, the decrement in night-driving performance occurring after LASIK would be clinically relevant in between 20% and 50% of the patients in the four treatment groups," Dr. Schallhorn said.

Dr. Schallhorn has no financial interest in any of the technology he discussed.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Shehzad Batliwala, DO, aka Dr. Shehz, discussed humanitarian ophthalmology and performing refractive surgery in low-resource, high-risk areas at the ASCRS Foundation Symposium.
(Image credit: Ophthalmology Times) ASCRS 2025: Advancing vitreous care with Inder Paul Singh, MD
(Image credit: Ophthalmology Times) The Residency Report: Study provides new insights into USH2A target end points
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
© 2025 MJH Life Sciences

All rights reserved.